CHCamille Hage

Camille Hage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camille Hage has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Durability of Respiratory Syncytial Virus Antibodies After Vaccination in Immunosuppressed Persons

    by Zeba Nauroz, Prasanthy Balasubramanian, Moreno Rodrigues, Shreya Arondekar, Isabella Sengsouk, Camille Hage, Maggie Chahoud, Xori Green, Woudase Gallo, Yolanda Eby, et al.

    Respiratory syncytial virus (RSV) antibody durability in immunosuppressed persons following RSV vaccination is unknown. In this observational cohort of immunosuppressed persons, peak responses occurred 1 month after vaccination, without significant waning by 6 months; adjuvanted vaccine recipients had higher responses. This suggests RSV antibody durability of at least 6 months and potential augmentation by adjuvanted vaccine.

  • Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients

    by Trevor S Johnston, Camille Hage, Aura T Abedon, Snigdha Panda, Jennifer L Alejo, Yolanda Eby, Dorry L Segev, Aaron A R Tobian, Andrea L Cox, William A Werbel, et al.

    Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization.


  • Speed of response to dopaminergic agents in prolactinomas

    by Camille Hage, Roberto Salvatori

    Purpose Hyperprolactinemia in the presence of a sellar lesion can be caused by prolactin secretion from the lesion, or by increased intrasellar pressure/compression of the pituitary stalk (“stalk effect”). The objective of this work was to determine the response to dopamine agonists (DAs) in bona fide prolactinomas presenting with a prolactin range similar to what can be seen in nonhormonal secreting pituitary tumors. Methods A descriptive study on 68 prolactinomas presenting with prolactin levels between 50 and 200 ng/mL in a tertiary center in the U.S.A. over 22 years. The main outcome was prolactin decrease from diagnosis to follow-up by 2 months from initiation of DA therapy. Results With a median time to follow-up from starting DA therapy of 5 weeks [IQR:4, 6], the median prolactin check showed normality at 11.85 ng/mL [IQR: 5.1, 29]. The median prolactin percent change was at 87% [IQR:67, 94] by 2 months. The majority (75%) of patients presenting had a 2/3 (67%) prolactin drop by 2 months, with more than 1/4 (25%) having a percent drop >95%. Conclusions A rapid decline in prolactin level can be seen in prolactinomas upon initiation of DA therapy. This significant prolactin drop restricts the ability to establish a threshold beyond which the diagnosis of prolactinoma could be excluded.